Crispr Therapeutics AG (NASDAQ:CRSP) major shareholder Corp /De/ Celgene sold 22,759 shares of Crispr Therapeutics stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $19.10, for a total transaction of $434,696.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Corp /De/ Celgene also recently made the following trade(s):

  • On Friday, December 1st, Corp /De/ Celgene sold 87,991 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.10, for a total transaction of $1,680,628.10.
  • On Wednesday, November 29th, Corp /De/ Celgene sold 4,263 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.25, for a total transaction of $82,062.75.
  • On Monday, November 27th, Corp /De/ Celgene sold 27,990 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.75, for a total transaction of $552,802.50.
  • On Friday, November 24th, Corp /De/ Celgene sold 26,010 shares of Crispr Therapeutics stock. The shares were sold at an average price of $20.00, for a total transaction of $520,200.00.
  • On Wednesday, November 22nd, Corp /De/ Celgene sold 256,000 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.76, for a total transaction of $5,058,560.00.
  • On Monday, November 20th, Corp /De/ Celgene sold 158,718 shares of Crispr Therapeutics stock. The shares were sold at an average price of $19.02, for a total transaction of $3,018,816.36.
  • On Friday, November 17th, Corp /De/ Celgene sold 51,282 shares of Crispr Therapeutics stock. The shares were sold at an average price of $18.44, for a total transaction of $945,640.08.
  • On Wednesday, November 15th, Corp /De/ Celgene sold 15,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.67, for a total transaction of $265,050.00.
  • On Monday, November 13th, Corp /De/ Celgene sold 65,093 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.76, for a total transaction of $1,156,051.68.
  • On Friday, November 10th, Corp /De/ Celgene sold 10,000 shares of Crispr Therapeutics stock. The stock was sold at an average price of $17.28, for a total transaction of $172,800.00.

Crispr Therapeutics AG (NASDAQ:CRSP) traded up $0.01 during trading hours on Thursday, hitting $18.53. 197,500 shares of the stock were exchanged, compared to its average volume of 142,711. Crispr Therapeutics AG has a twelve month low of $11.63 and a twelve month high of $25.00.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.02). The firm had revenue of $2.39 million during the quarter, compared to analyst estimates of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business’s quarterly revenue was up 54.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.77) EPS. analysts forecast that Crispr Therapeutics AG will post -2.46 EPS for the current year.

Several large investors have recently bought and sold shares of CRSP. Wells Fargo & Company MN raised its position in shares of Crispr Therapeutics by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares during the last quarter. Capital Investment Advisory Services LLC purchased a new stake in Crispr Therapeutics in the third quarter valued at approximately $193,000. Ark Investment Management LLC purchased a new stake in Crispr Therapeutics in the second quarter valued at approximately $206,000. Moloney Securities Asset Management LLC purchased a new stake in Crispr Therapeutics in the third quarter valued at approximately $235,000. Finally, Vanguard Group Inc. purchased a new stake in Crispr Therapeutics in the second quarter valued at approximately $273,000. 24.55% of the stock is owned by institutional investors and hedge funds.

CRSP has been the subject of a number of research reports. Barclays restated a “buy” rating and set a $29.00 target price on shares of Crispr Therapeutics in a research report on Friday, September 8th. Chardan Capital restated a “buy” rating on shares of Crispr Therapeutics in a research report on Monday, August 14th. BidaskClub cut shares of Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, December 2nd. SunTrust Banks restated a “hold” rating and set a $16.00 target price on shares of Crispr Therapeutics in a research report on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Hold” and a consensus price target of $22.38.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/crispr-therapeutics-ag-crsp-major-shareholder-sells-434696-90-in-stock.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.